Regulatory Focus™ > News Articles > Germany: IQWiG Finds Melanoma Drug Extends Life

Germany: IQWiG Finds Melanoma Drug Extends Life

Posted 03 May 2012 | By Louise Zornoza

A comparator study undertaken by Germany's Institute for Quality and Economy in Healthcare (IQWiG) has found the drug ipilimumab provides substantial additional benefit to patients suffering from advanced melanoma. 

In a three-pronged randomized clinical trial against "best supportive care", IQWiG found the drug extended life expectancy by 10 months as compared to 6.5 months with the comparator.  

The drug, however, is not without serious immune-mediated side effects as well.


Read more:

IQQiG - Ipilimumab - Nutzenbewertung gemäß § 35a SGB V

More Breaking News from RegLink


Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe